Legend Biotech(NASDAQ) LEGN

Legend Biotech Corporation is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative cell therapies for oncology and other indications. The company operates primarily in the United States, China, and Europe, with its lead product candidate being ciltacabtagene autoleucel, a CAR-T therapy for multiple myeloma.

Products and Services

• Ciltacabtagene autoleucel (cilta-cel) for multiple myeloma
• Portfolio of earlier-stage CAR-T therapies targeting various cancers
• Allogeneic gamma delta CAR-T and CAR-NK product candidates

Growth Outlook

• Strong pipeline with multiple CAR-T therapies in clinical trials
• Collaboration with Janssen Biotech enhances market reach
• Expansion into allogeneic therapies may diversify offerings

Financial Highlights

• Recent quarterly revenue of $305.1 million shows stability
• Trailing twelve months (TTM) revenue of $1.2 billion indicates growth potential
• Current ratio of 2.13 suggests strong liquidity position

Legend Biotech Corporation is positioned in the biotechnology sector, focusing on advanced cell therapies. The company has made significant strides in its research and development efforts, particularly with its lead product, cilta-cel, which is designed to treat multiple myeloma. The collaboration with Janssen Biotech is a strategic advantage, providing access to broader markets and resources. The growth outlook remains promising, with a robust pipeline of therapies in various stages of development. The company's financial health is underscored by a solid current ratio, indicating a strong ability to meet short-term obligations. Recent revenue figures reflect a stable performance, contributing to a positive narrative for potential investors. Overall, Legend Biotech Corporation presents an intriguing opportunity within the biotechnology landscape, driven by innovation and strategic partnerships.